X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HFB200301, a first-in-class agonistic anti-TNFR2 monoclonal antibody, in combination with tislelizumab, an investigational anti-PD-1 immune checkpoint inhibitor, for the treatment of advanced solid tumor.
Lead Product(s): HFB200301,Tislelizumab
Therapeutic Area: Oncology Product Name: HFB200301
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2023
Details:
HFB200603 is a single-digit nanomolar binder to human and cynomolgus BTLA, capable of blocking BTLA interaction with its ligand HVEM, inducing the production of inflammatory cytokines in the tumor microenvironment of different human tumor types.
Lead Product(s): HFB200603,Tislelizumab
Therapeutic Area: Oncology Product Name: HFB200603
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
Under the terms of the agreement, HiFiBiO Therapeutics will maintain control of the HFB200603 program, including global R&D and commercial rights. Novartis has agreed to supply tislelizumab for use in combination with HFB200603.
Lead Product(s): HFB200603,Tislelizumab
Therapeutic Area: Oncology Product Name: HFB200603
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 18, 2022
Details:
Under the terms of the agreement, HiFiBiO Therapeutics will maintain control of the HFB200301 program, including global R&D and commercial rights. Novartis has agreed to supply tislelizumab for use in combination with HFB200301.
Lead Product(s): HFB200301,Tislelizumab
Therapeutic Area: Oncology Product Name: HFB200301
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 15, 2022
Details:
HiFiBiO Therapeutics will use the proceeds from the financing to advance two lead antibody oncology assets into Phase I clinical trials - HFB200301, a novel anti-TNFR2 antibody and HFB301001, a differentiated second generation anti-OX-40 antibody.
Lead Product(s): HFB200301
Therapeutic Area: Oncology Product Name: HFB200301
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mirae Asset Financial Group
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing June 14, 2021
Details:
The partnership aims to advance HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment of COVID-19, through clinical development and commercial sale in Russia, pending approval from the Ministry of Health of the Russian Federation.
Lead Product(s): HFB30132A
Therapeutic Area: Infections and Infectious Diseases Product Name: HFB30132A
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Pharmsynthez
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 23, 2020
Details:
Partnership with ABL Bio supports HiFiBiO Therapeutics' rapid clinical advancement of its SARS-CoV-2 neutralizing antibody, HFB30132A, for the treatment of COVID-19 patients.
Lead Product(s): HFB30132A
Therapeutic Area: Infections and Infectious Diseases Product Name: HFB30132A
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: ABL Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 14, 2020
Details:
Through this collaboration, HiFiBiO will use its proprietary technology platforms to identify novel AML targets and anti-AML specific antibodies for Kite’s use in cell therapies.
Lead Product(s): Anti-AML specific antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Kite Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 03, 2020
Details:
The highly differentiated antibody, HFB30132A, has been rapidly identified, engineered, and evaluated in multiple preclinical studies. A Phase I single-IV administration ascending dose study will assess the safety, tolerability, and pharmacokinetics of HFB30132A.
Lead Product(s): HFB30132A
Therapeutic Area: Infections and Infectious Diseases Product Name: HFB30132A
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
Company leverages its unprecedented antibody drug discovery and development engine empowered by proprietary single-cell profiling technology to identify, engineer, and evaluate multiple neutralizing antibodies against SARS-CoV-2.
Lead Product(s): Mono & Bi-specific antibodies
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coronavirus Immunotherapy Consortium
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
